

## Liste der bewilligten Forschungsprojekte 2025 *Liste des projets de recherche acceptés en 2025*

### Basic research

**Bertoni Francesco** | Resistance to BTK Inhibitors in B-cell lymphomas: ERBB4 signalling and therapeutic vulnerabilities

*Faculty of Biomedical Sciences, USI, Institute of Oncology Research (IOR), Bellinzona, TI*  
CHF 363 933 | 36 months | KFS-6384-02-2025

**Bornhauser Beat** | Leveraging cell death vulnerabilities to augment immunotherapy

*Oncology, Universitäts-Kinderspital Zürich, Zürich*  
CHF 372 065 | 36 months | KFS-6481-08-2025

**Boyman Onur** | The role of matrix-producing neutrophils in shaping tumor architecture and immunity

*Center for Human Immunology, Universität Zürich (UZH), Zürich*  
CHF 374 741 | 36 months | KFS-6480-08-2025-R

**Fani Melpomeni** | GREAT-212: Gastrin-releasing peptide receptor antagonists for alpha therapy with lead-212

*Clinic of Radiology and Nuclear Medicine, Division of Radiopharmaceutical Chemistry, Universitätsspital Basel (USB), Basel*  
CHF 374 800 | 36 months | KFS-6508-08-2025

**Hugues Stephanie** | Cancer immunotherapy combinations based on novel A2AR negative allosteric modulators

*Pathology and Immunology, Université de Genève (UNIGE), Geneva*  
CHF 368 607 | 36 months | KFS-6358-02-2025-R

**Irving Melita** | Gene-engineered TCR-T-cell therapies against sarcoma for clinical translation

*Oncology, Université de Lausanne (UNIL), Epalinges*  
CHF 358 200 | 36 months | KFS-6348-02-2025

**Joller Nicole** | Impact of TIGIT-dependent tissue protection in cancer

*Quantitative Biomedicine, Universität Zürich (UZH), Zürich*  
CHF 358 367 | 36 months | KFS-6354-02-2025

**Konstantinidou Georgia** | Defining the role of PI3K $\delta$  in cancer-associated fibroblasts regulation to advance pancreatic cancer therapy

*Institute of Pharmacology, Universität Bern (UniBE), Bern*

CHF 373 603 | 42 months | KFS-6545-08-2025-R

**Läubli Heinz** | Glyco-engineering cell therapies for the treatment of cancer  
*Medical Oncology, Department of Biomedicine, Universitätsspital Basel (USB), Basel*  
CHF 359 280 | 36 months | KFS-6293-02-2025

**Meylan Etienne** | Functional characterization of a mitochondria-enriched subset of neutrophils in non-small cell lung cancer  
*Service de Chirurgie Thoracique, Centre hospitalier universitaire vaudois (CHUV), Lausanne*  
CHF 374 994 | 36 months | KFS-6342-02-2025

**Moor Andreas** | Targeting Plexin-B2 to prevent metastatic seeding  
*Department of Biosystems Science and Engineering (D-BSSE), Eidgenössische Technische Hochschule Zürich (ETHZ), Zürich*  
CHF 375 000 | 36 months | KFS-6368-02-2025

**Muller Mandy** | Investigating the molecular mechanisms underlying KSHV-associated cancer pathogenesis  
*IMUL, Centre hospitalier universitaire vaudois (CHUV), Lausanne*  
CHF 374 280 | 36 months | KFS-6448-08-2025

**Nageswara Rao Tata** | Targeting the inflammatory-metabolic axis to ameliorate disease progression in myeloid neoplasms  
*Klinik for Oncology and Hematology, HOCH Health Ostschweiz, St. Gallen*  
CHF 372 240 | 36 months | KFS-6308-02-2025-R

**Oricchio Elisa** | Decode how epigenetic heterogeneity contributes to lymphoma initiation and response to therapies  
*ISREC-SV, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne*  
CHF 370 200 | 48 months | KFS-6319-02-2025

**Peng Ren-Wang** | Targeting ferroptosis evasion mechanisms to overcome resistance to KRAS inhibitor therapy  
*Universitätsklinik für Thoraxchirurgie; Department of BioMedical Research (DBMR), Inselspital Bern, Bern*  
CHF 374 737 | 36 months | KFS-6559-08-2025

**Razansky Daniel** | Nanoparticle-induced hyperthermia for targeted brain cancer therapy via focused ultrasound activation  
*Institute for Biomedical Engineering, Universität Zürich (UZH), Zurich*  
CHF 367 624 | 36 months | KFS-6361-02-2025

**Roth Patrick** | Advanced engineering and optimization of novel multifunctional SynNotch CAR T cells for the treatment of glioblastoma  
*Department of Neurology, Universitätsspital Zürich (USZ), Zürich*

CHF 347 009 | 48 months | KFS-6383-02-2025-R

**Santoro Raffaella** | Genomic and functional analysis of nucleolar disruption and 3D genome dysregulation in NPM1c-driven leukemia

*Molecular Mechanisms of Disease, Universität Zürich (UZH), Zürich*

CHF 375 000 | 36 months | KFS-6454-08-2025

**Schwaller Jürg** | Functional characterization of a novel molecular dependency and potential therapeutic target of acute myeloid leukaemia (AML) driven by aberrant HOXA9/MEIS1 expression.

*Departement Biomedizin DBM, Universitäts-Kinderspital beider Basel (UKBB), Basel*

CHF 375 000 | 36 months | KFS-6295-02-2025

**Sommer Lukas** | The role of tumor-associated glial cells in melanoma progression and therapy response

*Anatomisches Institut, Universität Zürich (UZH), Zürich*

CHF 375 000 | 36 months | KFS-6455-08-2025

**Stoffel Markus** | Transforming the fibrotic stroma from limiting to enabling drug delivery for pancreatic cancer therapy

*Molecular Health Sciences, Eidgenössische Technische Hochschule Zürich (ETHZ), Zürich*

CHF 365 696 | 36 months | KFS-6325-02-2025

**Vannini Nicola** | Reprogramming ionic stress to rescue anti-tumour immunity and immunotherapy response

*Department of Oncology, Microbiology and Immunology (OMI), Université de Fribourg (UniFr), Fribourg*

CHF 367 017 | 36 months | KFS-6489-08-2025-R

**Wenes Mathias** | The metabolic-epitranscriptomic link in tumor-infiltrating CD8 T cells.

*Department of Medicine, Université de Genève (UNIGE), Genève*

CHF 374 809 | 36 months | KFS-6552-08-2025

**Wymann Matthias Paul** | Tackling lack of efficacy and therapeutic resistance to PI3Kalpha inhibition with covalent probes

*Departement Biomedizin DBM, Universität Basel, Basel*

CHF 249 948 | 24 months | KFS-6478-08-2025-R

**Zoete Vincent** | Structure-based analysis of TCR repertoires: Advancing epitope prediction through structural fingerprints with TCRfp

*Department of Oncology, Ludwig Cancer Research, Lausanne 15*

CHF 374 949 | 36 months | KFS-6476-08-2025-R

## Clinical Research – laboratory-oriented

**Alimonti Andrea** | Exploring PMN-MDSC heterogeneity in prostate cancer  
*Institute of Oncology Research, Institute of Oncology Research (IOR), Bellinzona*  
CHF 375 000 | 36 months | KFS-6323-02-2025

**Dawson Heather** | ctDNA and attacker-defender model as clinical tools in locally advanced colon cancer: A prospective, interdisciplinary study  
*Institute of Tissue Medicine and Pathology, Universität Bern (UniBE), Bern*  
CHF 362 587 | 48 months | KFS-6312-02-2025

**Galland Christophe** | Label-free Surface Enhanced Raman Spectroscopy (SERS) for the follow-up, detection of response and recurrence in glioblastoma  
*Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne*  
CHF 327 196 | 48 months | KFS-6391-02-2025-R

**Guerreiro Stücklin Ana S.** | Longitudinal molecular and spatial analyses of recurrent paediatric low-grade gliomas  
*Department of Oncology and Children's Research Center, Universität Zürich (UZH), Zurich*  
CHF 341 743 | 36 months | KFS-6375-02-2025

**Hottiger Michael O.** | Investigating the anti-tumour activity of PARP7 inhibitors alone or in combination with drugs inducing nucleic acid signalling in NSCLC spheroids  
*Department of Molecular Mechanisms of Disease, Universität Zürich (UZH), Zürich*  
CHF 371 031 | 36 months | KFS-6390-02-2025-R

**Jacob Francis** | LUMINA - Long-read scRNA-seq for Unraveling the tumor Microenvironment and Immune Niche Architecture  
*Department of Biomedicine, Universitätsspital Basel (USB), Basel*  
CHF 368 687 | 36 months | KFS-6522-08-2025

**Ludewig Burkhard** | Remodelling of lymph node immune and stromal cell niches in cancer of unknown primary  
*Medizinisches Forschungszentrum, HOCH Health Ostschweiz, St. Gallen*  
CHF 308 216 | 30 months | KFS-6494-08-2025

**Rapsomaniki Marianna** | AI-enabled precision oncology by multi-modal characterization of the tumour microenvironment in mesothelioma  
*Biomedical Data Science Center, Centre hospitalier universitaire vaudois (CHUV), Lausanne*  
CHF 362 272 | 48 months | KFS-6340-02-2025-R

**Recher Mike** | Elucidating the pathogenesis and lymphoma risk in persistent polyclonal B cell lymphocytosis  
*Biomedicine, Universitätsspital Basel (USB), Basel*  
CHF 375 000 | 36 months | KFS-6509-08-2025-R

**Rossi Davide** | Determinants of response to Bruton's Tyrosine Kinase inhibitors in marginal zone lymphomas

*Lymphoma & Genomics Research Program, Institute of Oncology Research (IOR), Bellinzona*

CHF 360 600 | 36 months | KFS-6381-02-2025

**Tugues Sonia** | T cell niches shaping response to neoadjuvant therapy in colorectal liver metastasis

*Institute of Experimental Immunology, Universität Zürich (UZH), Zurich*

CHF 366 433 | 36 months | KFS-6485-08-2025-R

## Clinical Research – patient-oriented

**Bink Andrea** | Amide proton transfer weighted and intra-voxel incoherent motion imaging in brain metastasis: a longitudinal study

*Neuroradiology, Universitätsspital Zürich (USZ), Zürich*

CHF 136 300 | 36 months | KFS-6324-02-2025-R

**Britschgi Christian** | A nutrition and exercise programme with olanzapine compared to olanzapine alone: a randomized controlled intervention trial in patients with advanced tumours

*Med. Onkologie und Hämatologie, Kantonsspital Winterthur (KSW), Winterthur*

CHF 334 740 | 42 months | KFS-6338-02-2025-R

**Herrera Fernanda** | A phase II non-randomized study of neoadjuvant induction chemotherapy and pembrolizumab followed by cisplatin chemo-radiation and pembrolizumab in locally-advanced cervical cancer

*Oncology, Centre hospitalier universitaire vaudois (CHUV), Lausanne*

CHF 375 000 | 36 months | KFS-6311-02-2025-R

**Le Rhun Emilie** | Repurposing vortioxetine for the treatment of glioblastoma: the ReVoGlio trial

*Department of Medical Oncology and Hematology, Universitätsspital Zürich (USZ), Zurich*

CHF 375 000 | 30 months | KFS-6464-08-2025-R

**Psoroulas Serena** | LATEST – LAttice vs Target dose Escalation: a randomised STudy

*Radiation Oncology, Universitätsspital Zürich (USZ), Zürich*

CHF 374 800 | 48 months | KFS-6524-08-2025-R

**Sandoval José Luis** | No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial (NoELA)

*Department of Oncology, Hôpitaux universitaires de Genève (HUG), Geneva*

CHF 374 151 | 48 months | KFS-6394-02-2025

**Seidel Kathleen** | MENTOR: Motor Eloquent Navigated Transcranial magnetic stimulation for Radiosurgery planning in brain metastasis  
*Universitätsklinik für Neurochirurgie, Inselspital Bern, Bern*  
CHF 59 700 | 6 months | KFS-6563-08-2025

**Stüssi Georg** | Bendamustine versus Cyclophosphamide and Fludarabine as Lymphodepleting Chemotherapy in Autologous Chimeric Antigen Receptor T-cell Therapy - A Randomized Trial (BALANCE-FC)  
*Servizio di Ematologie, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona*  
CHF 369 500 | 36 months | KFS-6557-08-2025

**Stute Petra** | Adherence to anti-estrogen therapy and correlation to blood steroidal biomarker in postmenopausal women with primary breast cancer  
Short title: STAY ON TRACK  
*Frauenheilkunde, Inselspital Bern, Bern*  
CHF 373 846 | 48 months | KFS-6409-02-2025

**Turco Fabio** | Intermittent androgen deprivation therapy in the era of androgen receptor pathway inhibitors: a phase 3 pragmatic randomized trial (DE-ESCALATE)  
*Oncology, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona*  
CHF 374 207 | 48 months | KFS-6379-02-2025

## Epidemiological research

**Ansari Marc** | World-wide collaboration in childhood liver cancer research  
*Faculté de médecine, Département de pédiatrie, gynécologie et obstétrique, Université de Genève (UNIGE), Genève 14*  
CHF 57 500 | 24 months | KFS-6288-02-2025

**Belle Fabiën** | Trajectories of growth and weight of childhood cancer patients: from birth until late adulthood  
*Childhood Cancer Research Group, Universität Bern (UniBE), Bern*  
CHF 371 948 | 36 months | KFS-6351-02-2025-R

**Bohlius Julia** | HPV, HIV, and schistosomiasis as synergistic risk factors for invasive cervical cancer  
*Swiss TPH, Epidemiology and Public Health, Schweizerisches Tropen- und Public Health-Institut (Swiss TPH), Allschwil*  
CHF 374 910 | 36 months | KFS-6550-08-2025

**Kuehni Claudia E.** | Exploring time trends and clusters of health behaviours among childhood cancer survivors in Switzerland  
*Institut für Sozial- und Präventivmedizin (ISPM), Universität Bern (UniBE), Bern*  
CHF 373 169 | 36 months | KFS-6346-02-2025

**Mehra Tarun** | Regional variation and determinants of treatment for early prostate cancer in Swiss cantons

*Medizinische Onkologie und Hämatologie, Universität Zürich (UZH), Zürich*  
CHF 47 445 | 12 months | KFS-6321-02-2025

## Health services research

**Vokinger Kerstin Noëlle** | Association between fast track approval and therapeutic value of cancer drugs— Improving expedited patient access to cancer drugs with high therapeutic value

*Institute of Law, Universität Zürich (UZH), Zürich*  
CHF 93 957 | 11 months | KFS-6386-02-2025

**Windisch Paul Yannick** | AUTOMated data extraction from clinical documents to reduce provider workload and improve standard operating procedure (SOP) adherence in RADiation ONCOlogy - AutoRadOnc

*Radiation Oncology, Kantonsspital Winterthur (KSW), Winterthur*  
CHF 146 392 | 18 months | KFS-6477-08-2025-R

## Psychosocial research

**Zwahlen Diana** | Bridging the gap in psychosocial care for cancer survivors post-treatment: Integrating targeted digital screening with psychosocial care navigation call

*Clinic for Psychosomatics, Universitätsspital Basel (USB), Basel*  
CHF 254 065 | 28 months | KFS-6423-02-2025

## Fellowships

**Benhassine Rym** | Uncovering and Exploiting Chemotherapy-Induced Proteins in Colorectal Cancer

*Department of Oncology, Université de Lausanne (UNIL), Epalinges*  
CHF 188 688 | 35 months | MD-PhD-6590-08-2025

**Jandek Madeleine** | Targeting PD-1 glycosylation to enhance multilineage immune checkpoint blockade

*Acute Geriatrics, Kantonsspital Winterthur (KSW), Winterthur*  
CHF 95 000 | 18 months | KFS-6523-08-2025 BIL

**Köhler Paulina Valerie Charlotte** | Deciphering dormancy in uveal melanoma: Unravelling tumor-intrinsic and microenvironmental pathways

*Innere Medizin, Felix-Platter-Spital, Cambridge*  
CHF 64 000 | 12 months | KFS-6363-02-2025 BIL

**Köpp Alexander** | Integrative Liquid Biopsy Platform for Molecular Monitoring and Therapy  
Response Prediction in Glioblastoma

*Neurology, Universitätsspital Zürich (USZ), Zurich*

CHF 67 000 | 12 months | KFS-6536-08-2025 BIL

**Riggenbach Elena** | Adaptive synergy in cervical cancer: integrating online adaptive  
external-beam radiotherapy with image-guided adaptive brachytherapy

*Universitätsklinik für Radio-Onkologie, Inselspital Bern, Bern*

CHF 55 000 | 12 months | KFS-6362-02-2025 BIL